Shanghai RAAS to acquire Boehringer Ingelheim China biopharma unit for up to 20 million yuan
Shanghai RAAS Blood Products Co., Ltd. announced on September 23, 2026, a plan to acquire 100% of Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. for a base price of 1 yuan, with an estimated acquisition price not exceeding 20 million yuan. The cash transaction aims to achieve full-chain control from R&D to commercial production for Shanghai RAAS's innovative drug business. The deal is subject to overseas antitrust approvals and must close by December 31, 2027.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary awaiting refresh
Summary awaiting refresh
Cross-source coverage
Reporting timeline
Shanghai RAAS to acquire Boehringer Ingelheim China unit for benchmark price of 1 yuan
Shanghai RAAS (002252) announced on September 23 that it plans to acquire 100% of Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. from Boehringer Ingelheim (China) Investment Co., Ltd. in a cash transaction. The acquisition aims to support the commercialization of SR604 injection and advance multiple innovative drug pipelines, achieving full-chain self-control from R&D to commercial production. The pricing follows a 'no cash/no debt' principle with a 'base price + acquisition price adjustment' mechanism, setting the base price at 1 yuan. The acquisition price is expected not to exceed 20 million yuan, though this is not a cap, with the final price determined by a 'final adjustment and settlement' clause. The target company, established in 2014, is a biopharmaceutical contract manufacturing site in Shanghai Zhangjiang, using mammalian cell technology. The deal is expected to enhance Shanghai RAAS's innovation drug industrialization capabilities and secure product exclusivity. The agreement was signed on September 23, 2026, and is subject to overseas antitrust approvals, with closing expected by December 31, 2027. In mid-2026, Shanghai RAAS reported revenue of 3.209 billion yuan and net profit of 661 million yuan.
Read sourceShanghai RAAS to Acquire Boehringer Ingelheim China Biologics Plant for Innovation Drug Autonomy
Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) announced on September 23, 2026, that it has signed an agreement to acquire 100% of Boehringer Ingelheim BioPharma (China) Co., Ltd. from Boehringer Ingelheim (China) Investment Co., Ltd. for cash. The target is a biologics manufacturing base in Shanghai's Zhangjiang Hi-Tech Park, with 6,000-liter production capacity and a stable team, offering one-stop services from clinical sample preparation to commercial production. Shanghai RAAS, a leading domestic blood products company, has positioned innovative drugs as its second growth curve, focusing on areas like coagulation and autoimmune diseases. Its lead candidate, SR604, a first-in-class hemophilia antibody drug, is in Phase III trials and has been produced at the Boehringer site. The acquisition aims to secure the supply chain for SR604 and future pipeline drugs, achieving full-chain autonomy from R&D to commercialization. Shanghai RAAS Deputy Chairman and General Manager Xu Jun stated the deal is a key step in the company's strategic upgrade to an innovative drug platform, enhancing self-sufficiency in industrialization and accelerating the commercialization of its pipeline.
Read sourceShanghai RAAS to Acquire 100% of Boehringer Ingelheim Biopharmaceuticals China
Shanghai RAAS Blood Products Co., Ltd. announced on September 23 that it plans to acquire 100% equity of Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. from Boehringer Ingelheim (China) Investment Co., Ltd. in a cash transaction. The acquisition aims to secure the commercial production of SR604 injection and support the development of multiple innovative drug pipelines, achieving full-chain self-control from R&D to commercial production. The base transaction price is set at 1 yuan, with an estimated final price not exceeding 20 million yuan, subject to the terms of the agreement. Post-completion, the target company will become a wholly-owned subsidiary of Shanghai RAAS. The report is attributed to Beijing Business Today reporters Wang Yinhao and Song Yuying.
Read sourceShow 5 older updatesHide older updates
Shanghai RAAS to Acquire Boehringer Ingelheim Biopharmaceuticals China for Up to 20 Million Yuan
On September 23, Shanghai RAAS Blood Products Co., Ltd. announced its plan to acquire 100% equity of Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. from Boehringer Ingelheim (China) Investment Co., Ltd. The acquisition will be made in cash, and upon completion, Boehringer Ingelheim Biopharmaceuticals China will become a wholly-owned subsidiary of Shanghai RAAS. The base transaction price is set at 1 yuan, with the final acquisition price expected not to exceed 20 million yuan, as determined by the agreement's terms. The move aims to achieve self-controlled, full-chain capabilities from R&D to commercial production for Shanghai RAAS's innovative drug business. The report is sourced from Beijing Business Today.
Read sourceShanghai RAAS Plans to Acquire Boehringer Ingelheim Biopharmaceuticals China for Up to 20 Million Yuan
Shanghai RAAS Blood Products Co., Ltd. (stock code: 002252) announced on September 23 that it plans to acquire 100% equity of Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. from Boehringer Ingelheim (China) Investment Co., Ltd. The acquisition, to be paid in cash, is intended to support the commercialization of SR604 injection and the orderly development of multiple innovative drug pipelines, achieving full-chain self-control from R&D to commercial production. The transaction price will be determined using a 'base price plus acquisition price adjustment' mechanism, with an estimated maximum of 20 million yuan. The announcement was reported by People's Financial Information on September 23.
Read sourceShanghai RAAS Signs Agreement to Acquire Boehringer Ingelheim Biopharmaceuticals China for Up to 20 Million Yuan
Shanghai RAAS Blood Products Co., Ltd. announced that it has signed an Acquisition and Sale Agreement and ancillary agreements on September 23, 2026, to acquire 100% equity of Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. from Boehringer Ingelheim (China) Investment Co., Ltd. The acquisition will be made in cash, with an estimated purchase price not exceeding RMB 20 million. The transaction is subject to necessary overseas antitrust approvals, and the closing must occur no later than December 31, 2027.
Read sourceShanghai RAAS to Acquire Boehringer Ingelheim China Biologics Plant, Boosting Innovation Drug Platform
Shanghai RAAS Blood Products Co., Ltd. announced on September 23, 2026, that it has signed an agreement to acquire 100% of Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. from Boehringer Ingelheim (China) Investment Co., Ltd. for cash. The acquisition, which includes a biologics manufacturing base in Shanghai's Zhangjiang Hi-Tech Park with 6,000-liter production capacity, is a key step in Shanghai RAAS's strategy to shift from blood products to innovative drugs. The base has been producing clinical samples for Shanghai RAAS's lead candidate, SR604, a global first-in-class hemophilia antibody drug currently in Phase III trials. Shanghai RAAS Deputy General Manager Xu Jun stated that the acquisition will give the company full control over the innovation drug value chain from R&D to commercial production, reducing supply and process risks. The deal aligns with China's policy to enhance self-sufficiency in high-end biologics manufacturing.
Read sourceShanghai RAAS to Acquire Boehringer Ingelheim Bio-Pharma China for Up to 20 Million Yuan
Shanghai RAAS Blood Products Co., Ltd. announced its intention to acquire 100% equity of Boehringer Ingelheim Bio-Pharma (China) Co., Ltd. from Boehringer Ingelheim (China) Investment Co., Ltd. The acquisition will be paid in cash, using a mechanism of a base price plus an acquisition price adjustment. The total consideration is expected not to exceed 20 million yuan. The move is aimed at achieving full-chain independent control of Shanghai RAAS's innovative drug business, from research and development to commercial production. The information was sourced from Cailian Press and published on East Money's company news section.
Read source